{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T10:10:58Z","timestamp":1771927858639,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,24]]},"DOI":"10.7759\/cureus.104163","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T09:19:33Z","timestamp":1771924773000},"source":"Crossref","is-referenced-by-count":0,"title":["Endophthalmitis Caused by \u03b1-Streptococcal Following Intravitreal Ranibizumab Biosimilar Administration Using a Prefilled Syringe"],"prefix":"10.7759","author":[{"given":"Kengo","family":"Utsunomiya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoichi","family":"Sakurada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Kasai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayane","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Kashiwagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1684\/ecn.2009.0170","article-title":"VEGF-A: a critical regulator of blood vessel growth","volume":"20","author":"Ferrara N","year":"2009","unstructured":"Ferrara N. VEGF-A: a critical regulator of blood vessel growth. Eur Cytokine Netw. 2009, 20:158-63. 10.1684\/ecn.2009.0170","journal-title":"Eur Cytokine Netw"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/ph16081140","article-title":"Intravitreal anti-vascular endothelial growth factor therapies for retinal disorders","volume":"16","author":"Hang A","year":"2023","unstructured":"Hang A, Feldman S, Amin AP, Ochoa JA, Park SS. Intravitreal anti-vascular endothelial growth factor therapies for retinal disorders. Pharmaceuticals (Basel). 2023, 16:10.3390\/ph16081140","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.52676","article-title":"Diabetic macular edema management: a review of anti-vascular endothelial growth factor (VEGF) therapies","volume":"16","author":"Cheema AA","year":"2024","unstructured":"Cheema AA, Cheema HR. Diabetic macular edema management: a review of anti-vascular endothelial growth factor (VEGF) therapies. Cureus. 2024, 16:e52676. 10.7759\/cureus.52676","journal-title":"Cureus"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa042760","article-title":"Pegaptanib for neovascular age-related macular degeneration","volume":"351","author":"Gragoudas ES","year":"2004","unstructured":"Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004, 351:2805-16. 10.1056\/NEJMoa042760","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1177\/24741264231191339","article-title":"Impact of prefilled syringes and masking on postintravitreal injection endophthalmitis","volume":"7","author":"Louis AM","year":"2023","unstructured":"Louis AM, Ali AM, Patel SB, et al.. Impact of prefilled syringes and masking on postintravitreal injection endophthalmitis. J Vitreoretin Dis. 2023, 7:382-8. 10.1177\/24741264231191339","journal-title":"J Vitreoretin Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-024-01002-0","article-title":"Clinical outcomes and experiences with prefilled syringes versus vials for intravitreal administration of anti-VEGF treatments: a systematic review","volume":"13","author":"Uzzan J","year":"2024","unstructured":"Uzzan J, Mapani A, Cox O, Bagijn M, Saffar I. Clinical outcomes and experiences with prefilled syringes versus vials for intravitreal administration of anti-VEGF treatments: a systematic review. Ophthalmol Ther. 2024, 13:2445-65. 10.1007\/s40123-024-01002-0","journal-title":"Ophthalmol Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12060962","article-title":"Clinical features, antibiotic susceptibilities, and outcomes of endophthalmitis caused by streptococcal infection: children vs. adults","volume":"12","author":"Yang Y","year":"2023","unstructured":"Yang Y, Wong Y, Li Y, et al.. Clinical features, antibiotic susceptibilities, and outcomes of endophthalmitis caused by streptococcal infection: children vs. adults. Antibiotics (Basel). 2023, 12:10.3390\/antibiotics12060962","journal-title":"Antibiotics (Basel)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-021-01449-6","article-title":"Post-traumatic endophthalmitis caused by streptococcus species in preschool children: clinical features, antibiotic susceptibilities and outcomes","volume":"36","author":"Yang Y","year":"2022","unstructured":"Yang Y, Sui W, Duan F, et al.. Post-traumatic endophthalmitis caused by streptococcus species in preschool children: clinical features, antibiotic susceptibilities and outcomes. Eye (Lond). 2022, 36:95-101. 10.1038\/s41433-021-01449-6","journal-title":"Eye (Lond)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2013.12.026","article-title":"Endophthalmitis caused by streptococcal species: clinical settings, microbiology, management, and outcomes","volume":"157","author":"Kuriyan AE","year":"2014","unstructured":"Kuriyan AE, Weiss KD, Flynn HW Jr, Smiddy WE, Berrocal AM, Albini TA, Miller D. Endophthalmitis caused by streptococcal species: clinical settings, microbiology, management, and outcomes. Am J Ophthalmol. 2014, 157:774-780.e1. 10.1016\/j.ajo.2013.12.026","journal-title":"Am J Ophthalmol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e31820a67e4","article-title":"Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies","volume":"31","author":"McCannel CA","year":"2011","unstructured":"McCannel CA. Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies. Retina. 2011, 31:654-61. 10.1097\/IAE.0b013e31820a67e4","journal-title":"Retina"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00063-1","article-title":"Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial","volume":"23","author":"Lanzetta P","unstructured":"Lanzetta P, Korobelnik JF, Heier JS, et al.. Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. Lancet. 23:1141-52. 10.1016\/S0140-6736(24)00063-1","journal-title":"Lancet"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.04.017","article-title":"HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration","volume":"127","author":"Dugel PU","year":"2020","unstructured":"Dugel PU, Koh A, Ogura Y, et al.. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020, 127:72-84. 10.1016\/j.ophtha.2019.04.017","journal-title":"Ophthalmology"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00010-1","article-title":"Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials","volume":"399","author":"Heier JS","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, et al.. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022, 399:729-40. 10.1016\/S0140-6736(22)00010-1","journal-title":"Lancet"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld PJ","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006, 355:1419-31. 10.1056\/NEJMoa054481","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"Heier JS","year":"2012","unstructured":"Heier JS, Brown DM, Chong V, et al.. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012, 119:2537-48. 10.1016\/j.ophtha.2012.09.006","journal-title":"Ophthalmology"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1995.01100120009001","article-title":"Results of the Endophthalmitis Vitrectomy Study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Endophthalmitis Vitrectomy Study Group","volume":"113","year":"1995","unstructured":"Results of the Endophthalmitis Vitrectomy Study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Endophthalmitis Vitrectomy Study Group. Arch Ophthalmol. 1995, 113.1479-96. 10.1001\/archopht.1995.01100120009001","journal-title":"Arch Ophthalmol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11185445","article-title":"The role of silicone oil in the surgical management of endophthalmitis: a systematic review","volume":"11","author":"Sinisi F","year":"2022","unstructured":"Sinisi F, Della Santina M, Loiudice P, Figus M, Casini G. The role of silicone oil in the surgical management of endophthalmitis: a systematic review. J Clin Med. 2022, 11:10.3390\/jcm11185445","journal-title":"J Clin Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S559156","article-title":"Systematic review of clinical practice guidelines for\u00a0post-cataract surgery endophthalmitis prophylaxis from 2008-2023","volume":"19","author":"Surawatsatien N","year":"2025","unstructured":"Surawatsatien N, Kasetsuwan P, Pruksacholavit J, et al.. Systematic review of clinical practice guidelines for\u00a0post-cataract surgery endophthalmitis prophylaxis from 2008-2023. Clin Ophthalmol. 2025, 19:3949-60. 10.2147\/OPTH.S559156","journal-title":"Clin Ophthalmol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-020-00270-w","article-title":"The role of systemic antimicrobials in the treatment of endophthalmitis: a review and an international perspective","volume":"9","author":"Grzybowski A","year":"2020","unstructured":"Grzybowski A, Turczynowska M, Schwartz SG, Relhan N, Flynn HW Jr. The role of systemic antimicrobials in the treatment of endophthalmitis: a review and an international perspective. Ophthalmol Ther. 2020, 9:485-98. 10.1007\/s40123-020-00270-w","journal-title":"Ophthalmol Ther"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1177\/24741264221116487","article-title":"Clinical practice update: management of infectious endophthalmitis after intravitreal anti-VEGF injection","volume":"6","author":"Merani R","year":"2022","unstructured":"Merani R, Johnson MW, McCannel CA, Flynn HW Jr, Scott IU, Hunyor AP. Clinical practice update: management of infectious endophthalmitis after intravitreal anti-VEGF injection. J Vitreoretin Dis. 2022, 6:443-51. 10.1177\/24741264221116487","journal-title":"J Vitreoretin Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/439964-endophthalmitis-caused-by--streptococcal-following-intravitreal-ranibizumab-biosimilar-administration-using-a-prefilled-syringe","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T09:19:34Z","timestamp":1771924774000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/439964-endophthalmitis-caused-by--streptococcal-following-intravitreal-ranibizumab-biosimilar-administration-using-a-prefilled-syringe"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.104163","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,24]]}}}